{"id":"NCT00772109","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults","officialTitle":"Lot Consistency, Immunogenicity, and Safety Study of Three Lots of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® Administered Intramuscularly in Adult Subjects Aged 18 to 64 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2009-05","completion":"2009-07","firstPosted":"2008-10-15","resultsPosted":"2011-08-10","lastUpdate":"2016-04-14"},"enrollment":4292,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Orthomyxoviridae Infection","Influenza","Myxovirus Infection"],"interventions":[{"type":"BIOLOGICAL","name":"Influenza Virus Vaccine USP Trivalent Types A and B","otherNames":[]},{"type":"BIOLOGICAL","name":"Influenza Virus Vaccine USP Trivalent Types A and B","otherNames":[]},{"type":"BIOLOGICAL","name":"Influenza Virus Vaccine USP Trivalent Types A and B","otherNames":[]},{"type":"BIOLOGICAL","name":"Influenza Virus Vaccine USP Trivalent Types A and B","otherNames":["Fluzone®"]}],"arms":[{"label":"Fluzone Intradermal Vaccine Lot 1","type":"EXPERIMENTAL"},{"label":"Fluzone Intradermal Vaccine Lot 2","type":"EXPERIMENTAL"},{"label":"Fluzone Intradermal Vaccine Lot 3","type":"EXPERIMENTAL"},{"label":"Fluzone Intramuscular Vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to test lot consistency of three different manufacturing lots and to generate safety and immunogenicity data of the investigational vaccine administered via the ID route.\n\nPrimary Objective:\n\n* To demonstrate lot consistency of the Fluzone ID manufacturing process.\n* To provide information concerning the immune response of Fluzone ID.\n\nSecondary Objectives:\n\nSafety\n\n* To describe the safety profile of subjects who receive of Fluzone ID.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) at Baseline and Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccines","timeFrame":"Baseline (Day 0) and 28 Days post-vaccination","effectByArm":[{"arm":"Fluzone Intradermal (ID) Vaccine Lot 1","deltaMin":23.5,"sd":null},{"arm":"Fluzone Intradermal (ID) Vaccine Lot 2","deltaMin":25.27,"sd":null},{"arm":"Fluzone Intradermal (ID) Vaccine Lot 3","deltaMin":25.29,"sd":null},{"arm":"Fluzone Intramuscular (IM) Vaccine","deltaMin":24.84,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":49,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["23499604"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":953},"commonTop":["Injection site erythema","Injection site pain","Injection site induration","Injection site swelling","Injection site pruritus"]}}